Trial Profile

A Phase III, multinational, post-neoadjuvant trial of sacituzumab govitecan for the treatment of newly-diagnosed high risk breast cancer patients who do not achieve a pathological complete response (pCR) following standard neoadjuvant therapy

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 04 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Oct 2019 New trial record
28 Sep 2019 According to an Immunomedics media release, this trial will be sponsored by GBG Forschungs-GmbH (Germany) under a collaboration with Immunomedics. Dr. med. Frederik Marme (MD, PhD, Section Lead for Gynecological Oncology, University Medical Center, Mannheim, Germany) is the lead investigator for this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com